![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
(HCV-TARGET) - Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
N Terrault, S Zeuzem, AM Di Bisceglie, JK Lim, PJ Pockros, LM Frazier, A Kuo, AS Lok, ML Shiffman, Z Ben Ari, T Stewart, MS Sulkowski, MW Fried, and DR Nelson for the HCV-TARGET Study Group
from Jules: of note, the authors report PPI use was associated with higher rate of failure; they also report high SVR/success with 8 weeks therapy, equal to 12 weeks:
![AASLD1.gif](../images/120315/120315-15/AASLD1.gif)
![AASLD2.gif](../images/120315/120315-15/AASLD2.gif)
![AASLD3.gif](../images/120315/120315-15/AASLD3.gif)
![AASLD4.gif](../images/120315/120315-15/AASLD4.gif)
![AASLD5.gif](../images/120315/120315-15/AASLD5.gif)
![AASLD6.gif](../images/120315/120315-15/AASLD6.gif)
![AASLD7.gif](../images/120315/120315-15/AASLD7.gif)
![AASLD8.gif](../images/120315/120315-15/AASLD8.gif)
![AASLD9.gif](../images/120315/120315-15/AASLD9.gif)
![AASLD10.gif](../images/120315/120315-15/AASLD10.gif)
![AASLD11.gif](../images/120315/120315-15/AASLD11.gif)
![AASLD12.gif](../images/120315/120315-15/AASLD12.gif)
![AASLD13.gif](../images/120315/120315-15/AASLD13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|